ArticleIn vivo (Athens, Greece)
Data Mining of the Japanese Adverse Drug Event Report Database and Animal Experiments for Assessment of Risks Associated With Pemafibrate.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimPemafibrate is a novel and selective peroxisome proliferator-activated receptor α modulator that has demonstrated favorable efficacy and safety in phase II or III trails. Compared to fenofibrate, a conventional fibrate, pemafibrate exerts a triglyceride-lowering effect at 1/500 of the dose, and the incidence rate of adverse drug reactions is one-ninth at these doses. The aim of this study was to obtain additional information on the safety of pemafibrate. PATIENTS AND
methodsThe Japanese Adverse Drug Event Report (JADER) database was analyzed, and the associations of three fibrates and six statins with rhabdomyolysis and acute renal failure were evaluated using reporting odds ratios and information components. Additionally, preclinical experiments were conducted in rats. Creatine phosphokinase (CK) levels were measured after a single administration of fibrates. The CK levels were also assessed when pemafibrate was co-administered with statins.
resultsData mining of the JADER database suggested associations between all fibrates and statins and rhabdomyolysis; however, no signal for acute renal failure was detected for pemafibrate. Signals for rhabdomyolysis were observed for some fibrates when combined with statins, whereas no signal was detected for pemafibrate. In rats, outlier CK levels were not observed after pemafibrate administration, and no significant increase was observed. CK levels were significantly increased by pravastatin treatment.
conclusionThe JADER analysis suggests that pemafibrate may be a safer alternative to conventional fibrates, with a potentially lower association with rhabdomyolysis and acute renal failure, even when co-administered with statins. Preclinical animal experiments support the results of the JADER analysis. However, large-scale prospective studies are needed to clarify the risks of pemafibrate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.